Both in Biotechnology
enGene Therapeutics vs Humacyte
Over the past year ENGN returned −73.7% and HUMA returned −69.2%; their daily moves had a correlation of 0.01.
ENGN −73.7% HUMA −69.2%Growth of $1, one year, split-adjusted
| Metric | ENGN | HUMA |
|---|---|---|
| Price | $1.72 | $0.4500 |
| Market cap | $115.3M | $125.0M |
| Today | +6.17% | +2.16% |
| 1 month | −4.4% | −5.9% |
| 6 months | −80.6% | −54.2% |
| Year to date | −81.0% | −53.1% |
| 1 year | −75.1% | −71.7% |
| Revenue growth (YoY) | — | +34.9% |
| Gross margin | — | −203.2% |
| Net margin | — | −9064.5% |
| P/E (TTM) | — | — |
| Price / sales | — | 58.9× |
| Net cash | $241.0M | $13.7M |
| Dividend yield | — | — |
| Volatility (60d) | 58.2% | 107.9% |
| Short % of float | 3.4% | 11.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).